ORGO — Organogenesis Holdings Inc.

Summary of Organogenesis Holdings, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Product Revenue: $225.1 million, up 78% year-over-year and 50% sequentially.
• Advanced Wound Care Revenue: $217.2 million, an 83% increase year-over-year.
• Surgical & Sports Medicine Revenue: $7.9 million, down 2% year-over-year.
• Gross Profit: $175.2 million, representing 78% of net product revenue, up from 75% last year.
• Operating Income: $63.3 million, up 519% from $10.2 million year-over-year.
• GAAP Net Income: $43.7 million, compared to $7.7 million last year.
• Adjusted EBITDA: $84.2 million, or 37% of total revenue, compared to $18.2 million or 14% last year.
• Cash Position: $94.3 million in cash and equivalents, down from $136.2 million year-over-year, with no debt obligations.

2. Strategic Updates and Business Highlights

• The company is focused on expanding its Advanced Wound Care product line and has successfully commercialized Dermagraft, enhancing its PMA product offerings.
• A new manufacturing and R&D facility in Smithfield, Rhode Island is under development to scale production.
• The ReNu program is progressing, with a rolling BLA submission expected to complete in the first half of 2026, which could transform treatment for knee osteoarthritis.
• Organogenesis aims to leverage recent CMS policy changes to gain market share, promoting PMA products over non-PMA alternatives.

3. Forward Guidance and Outlook

• For 2026, the company expects total net revenue to decline by 25% to 38% year-over-year, with Q1 projected to see a 50% revenue decline due to clinician confusion stemming from CMS commentary.
• Anticipated recovery in the second half of 2026, with expectations of substantial market share gains and improved financial performance, particularly in Q4.
• Adjusted EBITDA margins are expected to be in the high teens by the fourth quarter of 2026.

4. Bad News, Challenges, or Points of Concern

• The withdrawal of LCD coverage policies and CMS comments on discarded products have created significant clinical confusion, negatively impacting the utilization of PMA-approved products.
• The operating environment remains uncertain, with competitive pressures and pricing tactics affecting market dynamics.
• The company faces near-term challenges as it adapts to sweeping CMS changes, which have led to reduced reimbursement for non-PMA products.

5. Notable Q&A Insights

• Management indicated that the strong growth in Q4 was not significantly influenced by inventory pull-forward, as products are primarily used on patients.
• There is confidence in gaining market share despite the anticipated revenue decline, with expectations of improved competitive dynamics as the year progresses.
• The confusion surrounding CMS policy changes is viewed as a transitory issue that Organogenesis is actively working to address with its customers.

Overall, while Organogenesis achieved record financial results in Q4 2025, it faces significant challenges in 2026 due to external market factors and regulatory changes. However, management remains optimistic about long-term growth and market leadership.